Document Detail


Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor.
MedLine Citation:
PMID:  21030067     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To elucidate the mechanism of transforming growth factor (TGF)-β1 overexpression in prostate cancer cells.
METHODS: Malignant (PC3, DU145) and benign (RWPE1, BPH1) prostate epithelial cells were used. Phosphatase activity was measured using a commercial kit. Recruitment of the regulatory subunit, Bα, of protein phosphatase 2A (PP2A-Bα) by TGF-β type I receptor (TβRI) was monitored by coimmunoprecipitation. Blockade of TGF-β1 signaling in cells was accomplished either by using TGF-β-neutralizing monoclonal antibody or by transduction of a dominant negative TGF-β type II receptor retroviral vector.
RESULTS: Basal levels of TGF-β1 in malignant cells were significantly higher than those in benign cells. Blockade of TGF-β signaling resulted in a significant decrease in TGF-β1 expression in malignant cells, but not in benign cells. Upon TGF-β1 treatment (10 ng/mL), TGF-β1 expression was increased in malignant cells, but not in benign cells. This differential TGF-β1 auto-induction between benign and malignant cells correlated with differential activation of extracellular signal-regulated kinase (ERK). Following TGF-β1 treatment, the activity of serine/threonine phosphatase and recruitment of PP2A-Bα by TβRI increased in benign cells, but not in malignant cells. Inhibition of PP2A in benign cells resulted in an increase in ERK activation and in TGF-β1 auto-induction after TGF-β1 (10 ng/mL) treatment.
CONCLUSIONS: These results suggest that TGF-β1 overexpression in malignant cells is caused, at least in part, by a runaway of TGF-β1 auto-induction through ERK activation because of a defective recruitment of PP2A-Bα by TβRI.
Authors:
Nengwang Yu; James M Kozlowski; Irwin I Park; Lin Chen; Qiang Zhang; Danfeng Xu; Jennifer A Doll; Susan E Crawford; Charles B Brendler; Chung Lee
Related Documents :
6728727 - Dimethylsulphoxide stimulation of dome formation in cultured rat prostate epithelial ce...
20843707 - Effective enrichment of prostate cancer stem cells from spheres in a suspension culture...
20412587 - Pi3kp110-, src-, fak-dependent and dock2-independent migration and invasion of cxcl13-s...
12899227 - Incidence of neuroendocrine cells in the seminal vesicles and the prostate--an immunohi...
6728727 - Dimethylsulphoxide stimulation of dome formation in cultured rat prostate epithelial ce...
427877 - Cell population kinetic profile of the mouse thymus, and the changes induced by prednis...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2010-10-27
Journal Detail:
Title:  Urology     Volume:  76     ISSN:  1527-9995     ISO Abbreviation:  Urology     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-06     Completed Date:  2011-01-04     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1519.e8-13     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Inc. All rights reserved.
Affiliation:
Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / metabolism*,  pathology
Autocrine Communication
Cell Line, Tumor / metabolism
Enzyme Activation
Gene Expression Regulation, Neoplastic*
Humans
Male
Mitogen-Activated Protein Kinase 1 / metabolism*
Mitogen-Activated Protein Kinase 3 / metabolism*
Neoplasm Proteins / metabolism*
Phosphorylation
Prostate / metabolism
Prostatic Neoplasms / metabolism*,  pathology
Protein Phosphatase 2 / metabolism*
Protein Processing, Post-Translational
Protein-Serine-Threonine Kinases / metabolism*
RNA, Messenger / biosynthesis,  genetics
RNA, Neoplasm / biosynthesis,  genetics
Receptors, Transforming Growth Factor beta / metabolism*
Reverse Transcriptase Polymerase Chain Reaction
Transforming Growth Factor beta1 / biosynthesis*,  genetics
Grant Support
ID/Acronym/Agency:
P50 CA090386-06A2/CA/NCI NIH HHS; P50CA90386/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Neoplasm Proteins; 0/PPP2R2A protein, human; 0/RNA, Messenger; 0/RNA, Neoplasm; 0/Receptors, Transforming Growth Factor beta; 0/Transforming Growth Factor beta1; EC 2.7.1.11/TGF-beta type I receptor; EC 2.7.11.1/Protein-Serine-Threonine Kinases; EC 2.7.11.24/Mitogen-Activated Protein Kinase 1; EC 2.7.11.24/Mitogen-Activated Protein Kinase 3; EC 3.1.3.16/Protein Phosphatase 2
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Drug monitoring in systemic lupus erythematosus: a systematic review.
Next Document:  Everything you always wanted to know about evaluating prediction models (but were too afraid to ask)...